No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CDNA240816P17500
- 1.25
- -2.05-62.12%
15min DelayClose Jul 22 14:56 ET
1.25High1.20Low
1.25Open3.30Pre Close13 Volume20 Open Interest17.50Strike Price1.60KTurnover98.73%IV13.88%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry1.25Extrinsic Value100Contract SizeAmericanOptions Type-0.3327Delta0.0741Gamma15.10Leverage Ratio-0.0345Theta-0.0047Rho-5.02Eff Leverage0.0181Vega
Intraday
- 5D
- Daily
News
Where CareDx Stands With Analysts
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:CDNA) in the last three months.The following table encapsulates their recent
Express News | Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $16
CareDx, Inc (NASDAQ:CDNA) Held Back By Insufficient Growth Even After Shares Climb 31%
Despite an already strong run, CareDx, Inc (NASDAQ:CDNA) shares have been powering on, with a gain of 31% in the last thirty days. The last 30 days bring the annual gain to a very sharp 80%.
CareDx to Report Second Quarter 2024 Financial Results
Nephron Initiates CareDx at Hold Rating With $15 Price Target
07:57 AM EDT, 07/10/2024 (MT Newswires) -- Nephron Initiates CareDx at Hold Rating With $15 Price
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating
Craig-Hallum analyst William Bonello maintains $CareDx(CDNA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 75.0% and a total average return of 39.3% over the past
Comments
Investors may believe CareDx's strong revenue growth is not imminent, leading to a low P/S ratio. Expected future revenue decline could further decrease the P/S ratio, making a significant stock price rise unlikely.
Little Excitement Around CareDx, Inc's (NASDAQ:CDNA) Revenues As Shares Take 28% PoundingDespite a strong price move, CareDx's P/S ratio still trails the industry. The low P/S is due to the forecast for sliding revenue. Without significant change, drastic rise in the stock is unlikely.
$CareDx(CDNA.US$ 4.80 missed and ran 📈👀
$CareDx(CDNA.US$ Check out these highlights! ((. Reported revenue of $67.2 million, an increase of 7% over the second
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
1
Read more